RDPTF
Radiopharm Theranostics Ltd
$0.0200
0.00%
No data for this timeframe.
Vol
SEC Reports7
Recent Activity
May 7, 2026
SEC
Form 3 initial beneficial ownership filing for Dr. Dimitris Voliotis, newly appointed Chief Medical Officer of Radiophar
3 — Impact 2/10
Apr 23, 2026
SEC
Radiopharm Theranostics reported strong clinical progress across its pipeline, including completion of enrollment in a P
6-K — Impact 5/10
Apr 16, 2026
SEC
Radiopharm Theranostics announced completion of patient dosing in its U.S. Phase 2b trial of RAD 101 for diagnosing brai
6-K — Impact 7/10
Analyst Ratings
1Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Latest Reports
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
7 SEC filing reports analyzed. Sentiment: 4 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 5.3/10.
NEUTRAL
3
2/10
Form 3 initial beneficial ownership filing for Dr. Dimitris Voliotis, newly appointed Chief Medical
May 7, 2026
MIXED
6-K
5/10
Radiopharm Theranostics reported strong clinical progress across its pipeline, including completion
Apr 23, 2026
BULLISH
6-K
7/10
Radiopharm Theranostics announced completion of patient dosing in its U.S. Phase 2b trial of RAD 101
Apr 16, 2026
BULLISH
6-K
6/10
Radiopharm Theranostics announced that its Phase 1 'HEAT' clinical trial for 177Lu-RAD202 has advanc
Apr 8, 2026
BULLISH
6-K
7/10
Radiopharm Theranostics announced a clinical supply agreement with Siemens Healthineers for RAD101,
Apr 7, 2026
NEUTRAL
3
3/10
Noel Donnelly, a director of Radiopharm Theranostics Ltd, filed a Form 3 disclosing the grant of sto
Apr 2, 2026
BULLISH
6-K
7/10
Radiopharm Theranostics has dosed the first patient in its Phase 1 clinical trial of RAD 402, a nove
Mar 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution: 83% buy across 6 analysts — 1 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-03-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | -78.4% | — |
| Next FY 2027-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 498.9% | — |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Apr 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Mar 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Feb 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% | |
| Jan 1, 2026 | 1 | 4 | 1 | 0 | 0 | 83% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.